Phase 2 proof-of-concept study investigating the efficacy of navarixin in patients with chronic obstructive pulmonary disease
Phase of Trial: Phase II
Latest Information Update: 28 May 2013
Price : $35 *
At a glance
- Drugs Navarixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- 28 May 2013 Primary endpoint 'Forced-expiratory-volume-in-1-second' has been met.
- 28 May 2013 New trial record
- 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.